Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 11 healthy men, in a double-blind crossover design
- Dose used in the study
- 350 mg of Levagen+ or a maltodextrin placebo, in randomised order, with each condition followed by one bout of eccentric knee extensor exercise (24 sets of 10 contractions)
- Duration
- 120 hours after exercise
- What was measured
- Muscle strength, jump height, creatine kinase, muscle soreness and muscle biopsies
What the authors reported
Palmitoylethanolamide did not improve soreness, strength or jump performance, and had no effect on the molecular markers Pax7, p-FoxO1-3a, p62 and LC3BII/I, which rose with exercise regardless of treatment. Strength fell by up to about 40% and jump height by about 17% after exercise in both conditions, with the same rise in soreness and creatine kinase.
Limits of this study
11 participants, all men, and a single bout of exercise. The result runs against the earlier Mallard 2020 trial, which found lower blood markers but also no difference in soreness. The entry was checked against the abstract only, and funding was not listed in the record.
Source
PubMed 39086058 · doi:10.1249/mss.0000000000003517
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.